KEYTRUDA® (pembrolizumab) in the adjuvant treatment of melanoma resources
Prescribing Information [External link]
KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC or III melanoma and who have undergone complete resection.
KEYTRUDA® (pembrolizumab) in the treatment of advanced melanoma
KEYTRUDA as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma.
Patient education and support materials
Supporting documentation
Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website
